Evidence map›Paper›PMID 28770596›Full record

Trial reportJournal of the International AIDS Society2017

High rates of viral suppression in adults and children with high CD4+ counts using a streamlined ART delivery model in the SEARCH trial in rural Uganda and Kenya.

Dalsone Kwarisiima, Moses R Kamya, Asiphas Owaraganise, Florence Mwangwa, Dathan M Byonanebye, James Ayieko, Albert Plenty, Doug Black, Tamara D Clark, Bridget Nzarubara and 10 more

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of the International AIDS Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01864603 (Sustainable East Africa Research in Community Health), which is not on this map. Cited by 56 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed, 2 pooled it
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01864603 nacompletednot on this map

Sustainable East Africa Research in Community Health

TypeinterventionalSponsorUniversity of California, San FranciscoRan2013 to 2021Enrolled150,395ConditionsHIV, Tuberculosis, Hypertension, DiabetesArmsUniversal ART in a streamlined care model, Annual Community Health Campaigns, Targeted PrEP and Targeted testing interventions, Baseline community-based HIV and multi-disease testing
3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 2 syntheses or guidelines pooled it, 77 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Community-Wide Universal HIV Test and Treat Intervention Reduces Tuberculosis Transmission in Rural Uganda: A Cluster-Randomized Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Trial
  5. SEARCH Human Immunodeficiency Virus (HIV) Streamlined Treatment Intervention Reduces Mortality at a Population Level in Men With Low CD4 Counts.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021
    Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 3 countries.

Dalsone KwarisiimaInfectious Diseases Research Collaboration, Kampala, Uganda.
Moses R KamyaInfectious Diseases Research Collaboration, Kampala, Uganda.
Asiphas OwaraganiseInfectious Diseases Research Collaboration, Kampala, Uganda.
Florence MwangwaInfectious Diseases Research Collaboration, Kampala, Uganda.
Dathan M ByonanebyeInfectious Diseases Research Collaboration, Kampala, Uganda.
James AyiekoKenya Medical Research Institute, Nairobi, Kenya.
Albert PlentyDivision of HIV, Infectious Diseases & Global Medicine, University of California, San Francisco, CA, USA.
Doug BlackDivision of HIV, Infectious Diseases & Global Medicine, University of California, San Francisco, CA, USA.
Tamara D ClarkDivision of HIV, Infectious Diseases & Global Medicine, University of California, San Francisco, CA, USA.
Bridget NzarubaraInfectious Diseases Research Collaboration, Kampala, Uganda.
Katherine SnymanDivision of HIV, Infectious Diseases & Global Medicine, University of California, San Francisco, CA, USA.
Lillian BrownDivision of HIV, Infectious Diseases & Global Medicine, University of California, San Francisco, CA, USA.
Elizabeth BukusiKenya Medical Research Institute, Nairobi, Kenya.
Craig R CohenDepartment of Obstetrics, Gynecology & Reproductive Sciences, University of California, San Francisco, CA, USA.
Elvin H GengDivision of HIV, Infectious Diseases & Global Medicine, University of California, San Francisco, CA, USA.
Edwin D CharleboisDivision of HIV, Infectious Diseases & Global Medicine, University of California, San Francisco, CA, USA.
Theodore D RuelDivision of Infectious Diseases, Department of Pediatrics, University of California, San Francisco, CA, USA.
Maya L PetersenDepartment of Biostatistics and Epidemiology, Berkeley School of Public Health, Berkeley, CA, USA.
Diane HavlirDivision of HIV, Infectious Diseases & Global Medicine, University of California, San Francisco, CA, USA.
Vivek JainDivision of HIV, Infectious Diseases & Global Medicine, University of California, San Francisco, CA, USA.
University of California, San Francisco · USInfectious Diseases Research Collaboration · UGKenya Medical Research Institute · KEBerkeley Public Health Division · US

Funding

Ujima Mentoring ProgramP30MH062246 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Sheri Ann Lippman · 2001 to 2026
$57.4M
Reducing Failure-to-Initiate ART: Streamlined ART Start Strategy (START)U01AI099959 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HAVLIR, DIANE V · 2012 to 2016
$39.7M
San Francisco Vaccine and Prevention UnitUM1AI069496 · NIAID · PUBLIC HEALTH FOUNDATION ENTERPRISES · PI Susan Buchbinder, Diane V Havlir · 2012 to 2026
$30.5M
Targeted Learning using adaptive designs for HIV Epidemic control in East AfricaR01AI074345 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI PETERSEN, MAYA LIV, VANDERLAAN, MARK J · 2007 to 2023
$6.6M
National Institute of Allergy and Infectious Diseases (NIAID) U01AI099959NIAID NIH HHS R01 AI074345NIAID NIH HHS U01 AI099959NIAID NIH HHS UM1 AI069496NIMH NIH HHS P30 MH062246PEPFAR
6 · The paper itself

Abstract

introductionThe 2015 WHO recommendation of antiretroviral therapy (ART) for all HIV-positive persons calls for treatment initiation in millions of persons newly eligible with high CD4+ counts. Efficient and effective care models are urgently needed for this population. We evaluated clinical outcomes of asymptomatic HIV-positive adults and children starting ART with high CD4+ counts using a novel streamlined care model in rural Uganda and Kenya.

methodsIn the 16 intervention communities of the HIV test-and-treat Sustainable East Africa Research for Community Health Study (NCT01864603), all HIV-positive individuals irrespective of CD4 were offered ART (efavirenz [EFV]/tenofovir disoproxil fumarate + emtricitabine (FTC) or lamivudine (3TC). We studied adults (≥fifteen years) with CD4 ≥ 350/μL and children (two to fourteen years) with CD4 > 500/μL otherwise ineligible for ART by country guidelines. Clinics implemented a patient-centred streamlined care model designed to reduce patient-level barriers and maximize health system efficiency. It included (1) nurse-conducted visits with physician referral of complex cases, (2) multi-disease chronic care (including for hypertension/diabetes), (3) patient-centred, friendly staff, (4) viral load (VL) testing and counselling, (5) three-month return visits and ART refills, (6) appointment reminders, (7) tiered tracking for missed appointments, (8) flexible clinic hours (outside routine schedule) and (9) telephone access to clinicians. Primary outcomes were 48-week retention in care, viral suppression (% with measured week 48 VL ≤ 500 copies/mL) and adverse events.

conclusionsUsing a streamlined care model, viral suppression, retention and ART safety were high among asymptomatic East African adults and children with high CD4+ counts initiating treatment. CLINICAL TRIAL NUMBER: NCT01864603.

Indexed as

CD4 Lymphocyte CountDelivery of Health CareAdultAnti-HIV AgentsChildDrug Therapy, CombinationFemaleHIV InfectionsHIV SeropositivityHumansKenyaLost to Follow-UpMaleRural PopulationUgandaViral LoadAnti-HIV Agents

Identifiers

PMID28770596
PMCPMC5577724
OpenAlexW2734969121

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.